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To evaluate the antimalarial agent quinine as a potential in vivo probe for




Ten healthy adult volunteers received, by randomized crossover design,
either a single oral dose of quinine sulphate (600 mg) alone, or quinine sulphate
(600 mg) plus the CYP3A4 inhibitor troleandomycin (TAO; 500 mg every 8 h).
Plasma and urine samples were collected before quinine administration, and up to
48 h thereafter, then analysed by h.p.l.c. for both quinine and its CYP3A4-generated
metabolite, 3-hydroxyquinine. During both phases, the erythromycin breath test




Compared with control, TAO treatment significantly decreased the mean
time-averaged ERMBT result by 77% (95% CI, 68, 85%), the mean apparent oral




) by 45% (95% CI, 39, 52%), and the mean apparent
formation clearance of 3-hydroxyquinine (CL
 
3-OH) by 81% (95% CI, 76, 87%). There
was no correlation between the TAO-mediated percent decrease in the time-









TAO and control treatments were analysed separately, there were no significant













Quinine may be a useful probe to detect inhibition of liver CYP3A4
activity within an individual. Further studies are needed to determine whether it













In adult humans, cytochrome P450 (CYP) 3A4 is the
most abundant CYP isoform expressed in small intestinal
epithelial cells (enterocytes) and liver. CYP3A4 metabo-
lizes a vast number of currently used drugs [1, 2]. There
are large inter-patient differences in CYP3A4 content
and catalytic activity in both liver and intestine [3–5].
This variability appears to account in part for inter-
patient differences in dosing requirements of some
CYP3A4 drug substrates. The prototypical CYP3A4 sub-
strates cyclosporin and midazolam are  such  examples
[6–8]. CYP3A4 also plays a potentially important role in
the biotransformation of harmful dietary contaminants,
including mycotoxins (e.g. aflatoxin B1), pyrizolidine
alkaloids, and arylhydrocarbons (e.g. benzo[a]pyrene) [9,
10]. A logical but largely untested hypothesis is that
genetic mutations leading to altered CYP3A4 gene
expression may account for inter-individual differences in
susceptibility to toxicity from these xenobiotics [11].
To evaluate this hypothesis, a means of measuring
CYP3A4 activity in large numbers of individuals is
required. It may also be desirable in some circumstances
to measure selectively hepatic and not intestinal CYP3A4
activity, as intestinal CYP3A4 content can be greatly
influenced by dietary manipulations. For example, con-
sumption of a single glass of grapefruit juice causes a
significant reduction in intestinal CYP3A4 activity but
has little or no influence on hepatic CYP3A4 activity
[12]. Dietary differences may explain in part why the
relative activities of CYP3A4 in liver and intestine do not
correlate within an individual [5]. Thus if the goal of a
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CYP3A4 activity, it might be desirable to measure selec-
tively hepatic CYP3A4 activity only. To date, indirect
measurement of hepatic CYP3A4 activity involves intra-
venous injection of the probe (e.g. midazolam or the
erythromycin breath test). It would obviously be desir-
able to develop a safe oral probe that could selectively
measure liver CYP3A4 activity.
Quinine is one of the most widely prescribed drugs




malaria [13]. It is also used for the treatment of leg
cramps in the elderly. In healthy subjects, the absolute





indicating that the drug is nearly completely absorbed
into the systemic circulation following oral administra-
tion and undergoes little first-pass extraction. In addition,
grapefruit juice had no effect on the oral pharmacoki-
netics of quinine [15], confirming that first-pass metab-
olism of quinine by the intestine is negligible. The
fraction of a dose of quinine excreted unchanged in the
urine, however, is low (12%), and only small amounts
may be excreted into the bile [16], indicating that the
drug undergoes extensive metabolism. This is most likely
to occur in the liver and after it reaches the systemic
circulation. Moreover, using human liver microsomes, it
was shown that the metabolism of quinine to a major
metabolite, 3-hydroxyquinine, is catalysed primarily by
CYP3A4 [17, 18]. Based on these observations, we
hypothesized that if hepatic CYP3A4 is the rate-limiting
step in the elimination of quinine, this drug might serve
as a safe and inexpensive oral probe for hepatic CYP3A4
activity.
This hypothesis was tested in healthy volunteers using
two approaches. First, the effect of the mechanism-based,
selective CYP3A4 inhibitor troleandomycin (TAO) [19,
20] on the disposition of quinine and 3-hydroxyquinine
was examined. If hepatic CYP3A4 is rate limiting in the
elimination of quinine, the apparent oral clearance of
quinine and the apparent formation clearance of 3-
hydroxyquinine should decrease significantly. Second,
correlations were examined between hepatic CYP3A4
activity (as measured by the erythromycin breath test) and
the following pharmacokinetic measures of quinine:
apparent oral clearance, terminal elimination half-life,






Quinine hydrochloride dihydrate was purchased from
Fluka Chemical Corp. (Milwaukee, WI, USA). 3-
Hydroxyquinine was a gift from Dr P. Winstanley (Uni-
versity of Liverpool, Liverpool, UK). Cinchocaine (used
as an internal standard), sodium dodecyl sulphate, tet-
rabutylammonium bromide, hyamine (benzethonium)
hydroxide and thymolphthalein were purchased from
Sigma Chemical Co. (St Louis, MO, USA). The scintil-
lation cocktail, Emulsifier-Safe
 
®, was purchased from
Packard Instrument Co. (Meriden, CT, USA).
 
Preliminary study in female cancer patients
 
To determine the appropriate timing of TAO dosing to




, a preliminary study
was conducted in three adult female patients with ovarian
cancer (age, 45–71 years; weight, 53–96 kg). The Uni-
versity of Michigan Institutional Review Board approved
the protocol, and written informed consent was obtained
from all subjects. Each patient received a single oral dose
of TAO (500 mg), and the ERMBT was administered at
various times thereafter. To account for 
 
14C in breath
from preceding tests, it was determined prior to injection





20 min later (see below for calculation of the test result).
Since the ERMBT had never been administered on more
than two occasions within a 24 h period prior to this





from earlier injections might create error in the test result
after multiple tests. Therefore, only five tests were admin-
istered per patient.
 
Subjects and study design
 
Ten healthy volunteers, six women and four men, were
recruited for the study. Four of the women and one man
were African American, and the remaining five subjects
were Caucasian American (two women, three men).














 20 kg). Each subject was physically normal and had
no history of past illness or hypersensitivity to any of the
drugs used in the study. Before participating in the study,
each subject underwent a routine physical examination,
12-lead ECG, a blood chemistry screen, and a complete
blood count. No specific restraints were imposed on the
subjects except for a 72 h abstinence from any caffeine-
containing food and beverages, grapefruit products, and
alcohol prior to the study day and 48 h after quinine
administration.
The University of North Carolina Institutional
Review Board approved this protocol, and each subject
provided written informed consent prior to participation.
A randomized crossover design was used, consisting of
two phases, each separated by at least 2 weeks. Following
an overnight fast, a baseline ERMBT was obtained. For
the control phase, immediately following completion of
the ERMBT, a single oral dose of 600 mg quinine sul-
phate (Zenith Pharmaceuticals, Miami, FL) was given
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(time 0). Twenty-four and 48 h later, the ERMBT was
repeated. For the TAO phase, immediately following
completion of the ERMBT, 500 mg TAO (Pfizer, Inc.,
New York, NY) was given orally 2 h before quinine
administration and every 8 h thereafter until the end of
the 48 h period. An ERMBT was repeated immediately
prior to quinine administration (i.e. 2 h after the first
dose of TAO) and at 6, 24, and 48 h thereafter. During
each 48 h phase, a blood sample (5 ml) was drawn from
an indwelling catheter prior to and at 0.5, 1, 1.5, 2, 3,
4, 6, 8, 10, 12, 24, 30, 36 and 48 h after quinine
administration. Plasma was separated from blood cells by
centrifugation. Urine samples were collected before and
at 0–6, 6–12, 12–24, and 24–48 h intervals after quinine









C pending analysis for quinine and 3-
hydroxyquinine.
 
Erythromycin breath test (ERMBT)
 
The ERMBT was performed as described previously













erythromycin (Metabolic Solutions, Nashua, NH) were
diluted in 5 ml of 5% dextrose in water immediately
before its intravenous administration. Twenty minutes
after injection, the subject was instructed to exhale
through a tube, creating bubbles into a solution of
hyamine hydroxide:ethanol (50 : 50, v/v) to which a
trace amount of the blue indicator, thymolphthalein
(1%), had been added. When the blue dye turned clear,
2 mmol of carbon dioxide were trapped. Scintillation




C was measured by scintillation counting. ERMBT
results are expressed as the percentage of the administered






2 over the first hour after injection,




Plasma concentrations of quinine and 3-hydroxyquinine
were simultaneously quantified by a reversed-phase
h.p.l.c. method using a Hewlett Packard (Palo Alto, CA)
series 1100 system with fluorescence detection as previ-
ously described [22] with slight modification. In brief,















), adjusted to pH 2.1 with orthophosphoric acid.
Under this chromatographic condition, optimum separa-
tions of 3-hydroxyquinine, quinine, and internal standard
(cinchocaine) were achieved. Retention times were 3.6,
6.4 and 8.3 min, respectively. Plasma and urine samples
collected prior to quinine administration showed no
endogenous sources  of  interference. The  limits  of













, respectively. Inter- and
intra-day coefficients of variation in the assay for quinine




















 time  data  for  quinine  and  3-
hydroxyquinine from both treatment phases were analy-
sed by standard noncompartmental methods with the aid
of the software program WinNonlin (v2.1, Pharsight,

















) were obtained by visual
inspection of the plasma concentration-time curve. The







by log-linear regression of at least the last four data points
from the plasma concentration-time profile, and the ter-
















. The area under the curve (AUC) from time zero to





determined using the linear trapezoidal method. The





























is the last measured plasma concentration. The apparent




) was calculated as the




). The fraction of the dose











) was calculated by dividing
the cumulative urinary recovery (0–48 h) of quinine or
3-hydroxyquinine, respectively, by the dose. The renal




) was calculated by dividing
the 48 h urinary recovery of quinine by the


















All statistical analyses were performed using SAS (v6.10,
SAS Institute, Cary, NC). All pharmacokinetic measure-




 s.d. with 95% confi-
dence intervals (95% CI). Differences in pharmacokinetic
measurements between the control and TAO phases were





the ERMBT result at the various time points were eval-





by Dunnett’s test for multiple comparisons. The mean of
the three (control phase) or four (TAO phase, post TAO
administration) ERMBT results (see study design) was
determined for each subject (i.e. a time-averaged
ERMBT) and used as an index of hepatic CYP3A4
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the time-averaged ERMBT result (control or TAO
phase) and the various pharmacokinetic measures was

















A preliminary study was conducted in three cancer
patients to determine the optimal timing of TAO admin-
istration to maintain maximal inhibition of hepatic
CYP3A4 activity. The maximum decrease in the
ERMBT result occurred 2 h after TAO administration
(Figure 1, Subject 1), and at least 70% inhibition was
observed at 8 h (Subjects 1 and 2). CYP3A4 activity
appeared to have recovered to baseline by 24–44 h (Sub-
jects 1 and 3). Based on these results, the current study
was designed such that TAO was given as a pre-treatment
2 h before the administration of quinine and every 8 h
thereafter until the end of the study phase.
Shown in Figure 2 (upper panel) are typical ERMBT
results, obtained at three (control) or five (TAO) different
occasions over the 48 h study period, for a representative
subject (Subject F). Also shown (lower panel) is the
ERMBT result profile for the one atypical subject (Sub-
ject G). This subject experienced side-effects (nausea and
headaches) from TAO after two consecutive doses and
vomited after taking the third dose. Accordingly, TAO
was discontinued, but the subject soon felt better, and
the pharmacokinetic portion of the study was completed
without further TAO treatment. During the control
phase, the mean ERMBT result was unchanged over the
time course (Table 1). In contrast, during the TAO
phase, the mean ERMBT result significantly decreased
by 95% (95% CI, 93, 98%) 2 h after the first dose of
TAO and then increased at the end of the 8 h TAO
dosing interval (i.e. 6 h after quinine was given)
(Table 1). The mean ERMBT result then decreased at
24 h (i.e. 2 h after the TAO dose), but rose again at 48 h
(also 2 h after the TAO dose) (Table 1). Exclusion of
Subject G from the TAO phase did not change the mean
ERMBT values at the first three time points (-2, 0, and
6 h relative to quinine administration; see Table 1) but
did decrease the mean ERMBT values at the last two
time points (to 0.25 and 0.82 at 24 and 48 h, respec-
tively). TAO treatment significantly decreased the mean
time-averaged ERMBT by 77% (95% CI, 68, 85%) (Fig-
ure 3). This value was essentially unchanged if Subject G
was excluded (80%; 95% CI, 76, 85%). All tests of sta-
Figure 1 Time course of the effect of a single oral dose (500 mg) 
of troleandomycin (TAO) on hepatic CYP3A4 activity, as 
measured by the ERMBT, in three female cancer patients.  
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Figure 2 Time course of the effect of multiple doses of 
troleandomycin (TAO, 500 mg) on hepatic CYP3A4 activity 
(ERMBT) in a typical subject (Subject F) and in the one atypical 
subject (Subject G) in whom TAO was discontinued due to side-
effects.  represents the control phase (quinine alone),  
represents the TAO phase (quinine +TAO), and arrows represent 
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tistical significance remained unchanged with Subject G
excluded from the analysis.
Representative plasma concentration vs time profiles
for quinine and 3-hydroxyquinine after a single oral dose
of quinine sulphate (600 mg) for the two treatment
phases (control and TAO) are shown in Figure 4. The
corresponding profiles for subject G from 24 to 48 h (i.e.
when the ERMBT indicated no inhibition of CYP3A4)
were not obviously different from those in the other nine
subjects (not shown). However, there were only three
data points to consider. Therefore, Subject G was
included in the statistical analysis of the pharmacokinetic
data.
With TAO treatment, quinine concentrations were
higher, especially during the later time points, as com-
pared to the control phase (Figure 4, upper panel). The
formation of 3-hydroxyquinine was less during the TAO
phase than in the control phase throughout the time
course (Figure 4, lower panel). Pharmacokinetic measure-
ments for quinine and 3-hydroxyquinine are summarized
in Table 2 and 3, respectively. Values obtained from the
control phase agreed with those previously reported for
healthy volunteers [16, 23–25]. Compared with control,
TAO significantly increased the mean quinine AUC(0,•)
and Cmax by 90% (95% CI, 66, 113%) and 26% (95% CI,
16, 36%), respectively, and decreased the mean CL/F by
45% (95% CI, 39, 52%) (Table 2, Figure 3). In addition,
TAO significantly prolonged the mean terminal elimina-
tion half-life (t1/2) of quinine by 63% (95% CI, 49, 77%)
and increased the mean percentage of the quinine dose
excreted unchanged in the urine (0–48 h) by 101% (95%
CI, 63, 138%). There were no significant differences in
mean values for tmax and ClR of quinine between the
control and TAO phases (Table 2).
During both phases of the study, 3-hydroxyquinine
displayed formation rate-limited kinetics (Figure 4), as its
average terminal elimination half-life (14.3 and 25.7 h for
control and TAO phases, respectively) was not signifi-
cantly different from that for quinine (12.3 and 20.0 h
for control and TAO phases, respectively) (Tables 2 and
3). Compared with control values, coadministration of
TAO with quinine resulted in significant decreases in the
Table 1 Time course of the ERMBT result obtained from 10 healthy subjects given quinine alone (control phase) or quinine +TAO 
(TAO phase).
Subject
Time relative to quinine administration
-2 h 0 h 6 h 24 h 48 h
Quinine alone ERMBT (% of 14C exhaled h-1)
A 2.40 1.92 1.95
B 1.77 1.55 1.45
C 1.66 2.59 2.23
D 2.40 1.92 1.95
E 2.93 3.99 3.31
F 2.83 2.28 2.61
G 2.93 2.55 2.59
H 3.29 3.19 3.21
I 2.24 2.77 1.77
J 2.01 1.81 1.85
Mean ± s.d. 2.45 ± 0.54 2.46 ± 0.73 2.29 ± 0.62
95% CI 2.11, 2.78 2.00, 2.91 1.91, 2.68
Quinine +TAO ERMBT (% of 14C exhaled h-1)
A 2.04 0.20 0.28 0.14 0.96
B 2.15 0.13 0.46 0.11 0.70
C 2.23 0.04 0.64 0.15 0.56
D 3.34 0.46 1.56 0.81 1.35
E 3.78 0.12 0.68 0.18 0.86
F 2.64 0.03 0.68 0.35 0.50
G 2.35 0.02 0.91 2.03 2.36
H 2.71 0.02 0.77 0.19 1.11
I 1.84 0.10 0.53 0.13 0.41
J 1.76 0.08 0.99 0.22 0.94
Mean ± s.d. 2.48 ± 0.65 0.12 ± 0.13* 0.75 ± 0.35* 0.43 ± 0.60* 0.98 ± 0.57*
95% CI 2.08, 2.89 0.04, 0.20 0.53, 0.97 0.06, 0.80 0.62, 1.33
*Significantly different from corresponding value at -2 h (ANOVA followed by Dunnett’s test for multiple comparisons). Tests of statistical
significance were unchanged if Subject G were excluded (see Results).
S. Wanwimolruk et al.
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average AUC(0,•) (58%; 95% CI, 51, 65%), Cmax (75%;
95% CI, 70, 81%), the percentage of the dose excreted
in the urine as 3-hydroxyquinine (65%; 95% CI, 55,
74%), and apparent formation clearance (81%; 95% CI,
76, 87%) of 3-hydroxyquinine (Table 3). The mean ter-
minal elimination t1/2 of 3-hydroxyquinine was signifi-
cantly prolonged during the TAO phase. Although not
significant, the mean tmax increased nearly three-fold
(Table 3).
When data from the control and TAO phases were
analysed separately, there were no significant correlations
between  the  time-averaged  ERMBT  result  and  the
following: CL/F; single  plasma  quinine  or  3-
hydroxyquinine concentration at 12, 24, and 48 h;
Figure 3 Effect of TAO treatment on the time-averaged ERMBT 
result (upper panel), apparent oral clearance (CL/F) of quinine 
(middle panel), and apparent formation clearance of 3-
hydroxyquinine (CL3-OH) (lower panel). Bars and error bars denote 
the average and standard deviation, respectively. Asterisks (*) 
indicate that the mean value from the TAO phase statistically 






























































Figure 4 Plasma concentration vs time profiles of quinine and 3-
hydroxyquinine following administration of a single oral dose of 
quinine sulphate (600 mg) to a representative subject (Subject B). 
Open symbols represent the control phase (quinine alone); solid 
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Table 2 Pharmacokinetics of quinine following a single oral dose 
(600 mg) of quinine sulphate to 10 healthy subjects during two 
treatment phases: control (quinine alone) and TAO (quinine 
+TAO). Data are presented as mean ±s.d. (95% CI).
Measure Control phase TAO phase
AUC(0,•)
(mg l-1 h)
63 ± 10 (57–69) 118 ± 27* (102–135)
Cmax (mg l-1) 3.2 ± 0.5 (2.9–3.4) 3.8 ± 0.6** (3.5–4.2))
tmax (h) 3.3 ± 1.8 (2.2–4.4) 3.6 ± 2.4 (2.1–5.1)
CL/F (l h-1) 9.8 ± 1.8 (8.7–10.9) 5.3 ± 1.0* (4.6–5.9)
t1/2 (h) 12.3 ± 1.7 (11.2–13.3) 20.0 ± 4.5* (17.2–22.8)
fe,Q (0,48 h) 10.1 ± 2.4 (8.6–11.6) 19.6 ± 5.5* (16.2–23.1)
CLR (l h-1) 0.97 ± 0.21 (0.84–1.10) 1.03 ± 0.35 (0.82–1.25)
AUC(0,•), area under the plasma concentration-time curve from zero
to infinite time; Cmax, peak concentration; tmax, time to reach Cmax;
CL/F, apparent oral clearance; t1/2, terminal elimination half-life; fe,Q,
percent of the dose excreted unchanged in the urine; CLlR, renal
clearance. *P < 0.001; **P < 0.01 (paired Student’s t-test).
Quinine as a probe for hepatic CYP3A4
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CL3-OH; and the metabolite-to-parent AUC ratio. There
were also no correlations between the ERMBT result at
24 and 48 h and the corresponding plasma concentra-
tions. When data from the two treatment groups were
pooled, statistically significant correlations existed
between the time-averaged ERMBT result and each of
the aforementioned indices. However, these correlations
resulted solely from the two distinct clusters created by
control and TAO-treated subjects. Within subjects, there
were no correlations between the percent TAO-mediated
decreases in the ERMBT result and quinine CL/F, or
between the percent decreases in the ERMBT result and
CL3-OH.
Discussion
Previous studies have established that TAO is a potent
and selective inhibitor of human hepatic CYP3A4 in
vivo, as shown by considerable reductions (>75%) in the
ERMBT result [19] and systemic clearances of the
CYP3A4 substrates midazolam and alfentanil [20]. The
current study, utilizing the ERMBT, demonstrated that
TAO administered every 8 h resulted in continuous
potent inhibition of CYP3A4 activity throughout the
entire 48 h period. The inhibitory effect appeared to
abate slightly at the end of the first TAO dosing interval
(i.e. 6 h after quinine was administered) (Table 1), sug-
gesting that dosing intervals greater than 8 h would
result in less inhibition. The inhibitory effect also
appeared to abate between 24 and 48 h (Table 1). In
rats, TAO treatment has been shown to increase CYP3A
mRNA production and presumably CYP3A enzyme
synthesis [26]. If this is also the case in humans, this
mechanism could account for the gradual rise in
CYP3A4 activity and may limit the usefulness of TAO
for chronic inhibition.
During the TAO phase, the mean apparent oral clear-
ance (CL/F) of quinine significantly decreased by 45%
compared with control. Since quinine is essentially com-
pletely absorbed into the systemic circulation [14], and
TAO had only a modest effect on mean Cmax and tmax,
the reduction in CL/F by TAO treatment was primarily
due to inhibition of the systemic clearance of quinine.
Therefore, because the mean renal clearance was also
unchanged, the effect of TAO was likely to be on the
hepatic clearance of quinine. The mean apparent forma-
tion clearance of 3-hydroxyquinine (CL3-OH) was also
significantly reduced by TAO treatment (81%), consistent
with previous in vitro studies demonstrating that the for-
mation of 3-hydroxyquinine is mainly catalysed by
CYP3A4 [17, 18]. Thus, the present study demonstrates
that hepatic CYP3A4 accounts, on average, for at least
45% of quinine CL/F and up to 81% of CL3-OH. Cor-
respondingly, this infers that up to 55% of CL/F may be
non-CYP3A4 mediated. At least seven metabolites of
quinine have  been  detected  in  human urine,  with
three of these being identified as 3-hydroxyquinine, 2¢-
oxoquininone, and quinine glucuronide [27]. The
enzymes responsible for the latter two pathways are not
known. The conclusion that hepatic CYP3A4 is a major
pathway for the elimination of quinine is also consistent
with the in vivo observation of a six-fold increase in
quinine CL/F following pretreatment with rifampicin
[25], a prototypical CYP3A4 inducer. However, it is
possible, that intestinal CYP3A4-mediated metabolism
could become important in the disposition of quinine
after treatment with rifampicin (or other CYP3A4
inducers).
Mirghani et al. [28] reported that coadministration of
quinine with the CYP3A4 inhibitor ketoconazole led to
a significant decrease (31%) in both the mean quinine
CL/F and 3-hydroxyquinine AUC(0,•). The greater per-
cent reductions observed in the current study suggest that
TAO is more effective than ketoconazole as an inhibitor
of CYP3A4 in vivo. It is also likely that TAO is a more
selective inhibitor than ketoconazole, as the latter has
been shown to inhibit the secretory (efflux) transporter
P-glycoprotein (P-gp) [29–31]. Located on the apical
(lumenal) surface of human enterocytes [32], P-gp acts
to extrude its substrates from the interior of the entero-
cyte back into the intestinal lumen, often leading to a
decrease in the fraction of the dose absorbed. There is
considerable overlap between CYP3A4 and P-gp sub-
strates [33], potentially rendering it difficult to distinguish
the effects of ketoconazole on the two proteins. In con-
trast to ketoconazole, we have found that TAO does not
inhibit P-gp in the human intestinal cell line Caco-2
[34]. Collectively, these observations suggest that TAO
Table 3 Pharmacokinetics of 3-hydroxyquinine following a single 
oral dose (600 mg) of quinine sulphate to 10 healthy subjects 
during two treatment phases: control (quinine alone) and TAO 
(quinine +TAO). Data are presented as mean ± s.d. (95% CI).
Measure Control phase TAO phase
AUC(0,•)
(mg l-1 h)
7.7 ± 3.1 (5.8–9.5) 3.4 ± 2.2* (2.0–4.7)
Cmax (mg l-1) 0.32 ± 0.11 (0.25–0.38) 0.08 ± 0.03* (0.06–0.09)
tmax (h) 3.2 ± 1.8 (2.0–4.3) 9.4 ± 8.2 (4.3–14.5)
t1/2 (h) 14.3 ± 2.6 (12.7–15.9) 25.7 ± 11.7** (18.5–33.0)
fe,3-OH 7.1 ± 1.6 (6.1–8.2) 2.5 ± 1.2* (1.7–3.3)
CL3-OH (l h-1) 0.69 ± 0.17 (0.59–0.80) 0.13 ± 0.07* (0.09–0.17)
AUC(0,•), area under the plasma concentration-time curve from zero
to infinite time; Cmax, peak concentration; tmax, time to reach Cmax;
t1/2, terminal elimination half-life; fe,3-OH, fraction of the dose
excreted in urine as 3-hydroxyquinine; CL3-OH, apparent formation
clearance of 3-hydroxyquinine. *P < 0.001; **P < 0.01 (paired Stu-
dent’s t-test)
S. Wanwimolruk et al.
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may be superior to ketoconazole as an experimental
means of selectively inhibiting human CYP3A4 activity
in vivo.
It is not known whether quinine is hydroxylated by
polymorphically expressed CYP3A5, which shares 84%
amino acid sequence homology with CYP3A4 [35]. If
so, variability in the expression of CYP3A5 may have
influenced the changes in quinine disposition. Interest-
ingly, half of the subjects were African-American, who
have been reported to possess at least one CYP3A5 allele
at a greater frequency compared with Caucasians [36].
TAO inhibits CYP3A5 to a much lesser extent compared
to CYP3A4 (K.E. Thummel & D.J. McConn, University
of Washington, personal communication). Therefore, if
quinine  were  metabolized by  CYP3A5, the  TAO-
mediated decrease in quinine CL/F in CYP3A5 expres-
sors would  be predicted  to  be  less  compared  with
nonexpressors. Since the current group of subjects was
neither genotyped nor phenotyped for CYP3A5, the
influence of CYP3A5 expression on quinine disposition
cannot be ascertained at present.
There is large inter- and intra-individual variation in
human CYP3A4 activity, between 10-fold and 40-fold,
depending on the method used and the population stud-
ied [4, 5, 7]. This large variability in CYP3A4 activity
accounts for much of the inter- and intra-patient varia-
tions in the disposition of many CYP3A4 substrates [6].
The search for a suitable probe (biomarker) to assess
hepatic CYP3A4 activity has therefore been intense.
Many CYP3A4 probes have been proposed, including
the ERMBT [19], the ratio of endogenous cortisol to
6b-hydroxycortisol [37], and midazolam systemic clear-
ance [7, 8]. The utility, suitability, and limitation(s) of
each have been discussed elsewhere in detail [6, 38].
It was anticipated that results from the current study
would substantiate the use of quinine as the first oral
probe capable of quantifying hepatic CYP3A4 activity.
In support of this, following TAO treatment, both the
mean CL/F of quinine and CL3-OH decreased in parallel
with the mean time-averaged ERMBT result (Figure 3),
suggesting that quinine may be suitable to assess inhibition
of hepatic CYP3A4. However, within an individual, there
were no correlations between the percent decrease in
either quinine CL/F or CL3-OH and the percent decrease
in the ERMBT result. In addition, time-averaged
ERMBT results from the control or TAO phase did not
correlate with either quinine CL/F or CL3-OH. The
absence of such correlations may not necessarily mean
that no correlation existed, as the sample size (10) could
only detect a strong correlation (r > 0.8) with 85% prob-
ability. It should also be noted that the different CYP3A4
probes generally fail to correlate with one another, and
multiple factors may account for these lack of correlations
[39, 40]. Future studies will examine whether quinine
CL/F, or other surrogates, can predict the CL/F of other
CYP3A4 substrates, such as midazolam.
In summary, using TAO as a chemical ‘knockout’ for
CYP3A4, we have confirmed that a major pathway for
the metabolism of quinine in vivo is mediated by hepatic
CYP3A4. Compared with ketoconazole, TAO appears to
be the experimental treatment of choice to ablate
CYP3A4 activity in vivo. Because CYP3A4 plays a prom-
inent role in quinine elimination, quinine may serve as
a useful probe to assess within-subject inhibition of liver
CYP3A4 activity in certain circumstances. For example,
this approach can be easily performed in patients already
receiving quinine as treatment or prophylaxis for malaria.
Further studies are needed to determine whether quinine
can provide a quantitative measure of CYP3A4 activity
suitable for intersubject comparison.
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